GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

It's been a tough year for Novo Nordisk, the Danish pharmaceutical company behind the GLP-1 drugs Ozempic and Wegovy. Competitors are nipping at its heels, cheaper knockoffs have been eating into ...

Novo Nordisk stock (NVO ... Ozempic sales for the quarter were $4.9 billion, or about 3% ahead of estimates. Pressure on Wegovy sales could ease as the company sees a slowing of compounded ...

Novo Nordisk stock reported strong sales growth ... Net income for the quarter rose 14% to 29 billion DKK ($4.4 billion). According to S&P Global Market Intelligence data, that works out to ...

Novo Nordisk is expected to post earnings of $0.88 per share for the current quarter, representing a year-over-year change of +35.4%. Over the last 30 days, the Zacks Consensus Estimate has ...

Also Read: CVS Caremark To Place Novo Nordisk’s Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment Insulin sales increased 4% to 14.9 billion Danish kroner, and Rare disease sales ...

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients starting at $199 a month as easy access to cheaper copycats comes to an end. The one-time offer—available ...

One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk’s outlook is brightening. Novo Nordisk, the Danish company that produces the semaglutide ...

FRANKFURT, Germany — (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with ...